<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344094</url>
  </required_header>
  <id_info>
    <org_study_id>IRB10681A</org_study_id>
    <nct_id>NCT03344094</nct_id>
  </id_info>
  <brief_title>Mechanism of Action of Ocrelizumab in Multiple Sclerosis</brief_title>
  <official_title>Mechanism of Action of Ocrelizumab in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and
      stops MS inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will investigate immune cell subsets, and how the cells are modified by this
      therapy over a 1-year period in 25 subjects. Blood will be drawn at baseline, 2 weeks, 6 mo,
      and 12 mo.

      Immune subsets will be analyzed by flow cytometry. Data are analyzed with ANOVA with repeated
      measures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune subsets, measured through lymphocyte surface marker stains, from patients, before and after ocrelizumab (Ocrevus) therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Mononuclear cells (MNC) will be stained, for flow cytometry, with marker antibodies to B cells.
The change in the percentage of each subset will be compared before and after treatment with paired T tests and ANOVA.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Immune System Diseases</condition>
  <arm_group>
    <arm_group_label>MS-ocrelizumab treated</arm_group_label>
    <description>ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS untreated</arm_group_label>
    <description>age- and sex-matched untreated MS controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <description>age- and sex-matched untreated healthy controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS interferon-treated</arm_group_label>
    <description>MS with ongoing interferon-beta therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ocrelizumab</intervention_name>
    <description>FDA-approved MS drugs</description>
    <arm_group_label>MS-ocrelizumab treated</arm_group_label>
    <other_name>interferon-beta</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      frozen cells and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MS and healthy controls from the U of Chicago Neurology Clinic population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who are eligible for Ocrelizumab therapy based on FDA criteria

        Exclusion Criteria:

          -  All patients who are ineligible for Ocrelizumab therapy based on FDA criteria.

          -  Prior treatment with Alemtuzumab or stem cell therapy, or immune abnormalities that
             would interfere with planned tests.

          -  Hepatitis B and HIV infections.

          -  Pregnant or lactating women.

          -  Hypersensitivity to trial medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>anthony t reder, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>anthony t reder, md</last_name>
    <phone>7737026204</phone>
    <email>areder@neurology.bsd.uchicago.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mildred valentine, bs</last_name>
    <phone>7737029812</phone>
    <email>mvalenti@neurology.bsd.uchicago.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael r Ludwig, bs</last_name>
      <phone>773-702-8604</phone>
      <email>io-ura@lists.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>sandra lieneck, bs</last_name>
      <phone>773-834-1811</phone>
      <email>sleineck@neurology.bsd.uchicago.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

